Status:
UNKNOWN
Efficacy and Safety of Ainuovirine Treating With AIDS Patients
Lead Sponsor:
Guangzhou 8th People's Hospital
Conditions:
HIV/AIDS
Eligibility:
All Genders
18-60 years
Brief Summary
Ainuovirine is the third generation of non nucleoside reverse transcriptase inhibitors(NNRTIs), for the treatment of HIV-1 infected adults. The existing clinical studies show that Ainuovirine is safe ...
Detailed Description
This study is an open-label, multicentered, single-arm and phase IV clinical trial. 450 HIV-infected patients who received Ainuovirine regimen (150mg, oral, qd) were included. At day 1 (1st collectio...
Eligibility Criteria
Inclusion
- Diagnosis of HIV infection 18-60 years old Patients who are prescribed to take Ainuovirine regimen . Sign informed consent
Exclusion
- Patients who are participating in other interventional clinical trials;
- Patients who previously participated in the ACC007 study.
Key Trial Info
Start Date :
May 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT05420246
Start Date
May 1 2022
End Date
December 31 2025
Last Update
June 15 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Guangzhou 8th People's Hospital, Guangzhou Medical University.
Guangzhou, Guangdong, China, 510060